Evidence map›Paper›PMID 41501311›Full record

SynthesisDrugs2026

PCSK9 and ANGPTL3 Inhibitors in Homozygous Familial Hypercholesterolemia: A Meta-analysis of Randomized Clinical Trials.

Ibadete Bytyçi, Michael Y Henein, Sefer Bytyqi, Mentor Shatri, Drilon Gashi, Endrit Dragusha, Rozafa Koliqi, Shpend Elezi, Adrian V Hernandez, Maciej Banach

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ibadete BytyçiMedical Faculty, University of Prishtina, Prishtina, Kosovo.
Michael Y HeneinImperial College of London, London, UK.
Sefer BytyqiRiinvest University, Prishtina, Kosovo.
Mentor ShatriClinic of Cardiology, University Clinical Centre of Kosovo, Prishtina, Kosovo.
Drilon GashiImperial College of London, London, UK.
Endrit DragushaClinic of Cardiology, University Clinical Centre of Kosovo, Prishtina, Kosovo.
Rozafa KoliqiDepartment of Clinical Pharmacy and Biopharmacy, Pharmacy Division, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo.
Shpend EleziMedical Faculty, University of Prishtina, Prishtina, Kosovo.
Adrian V HernandezHealth Outcomes, Policy, and Evidence Synthesis (HOPES) group, Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, 06269, USA.
Maciej BanachFaculty of Medicine, The John Paul II Catholic University of Lublin, Lublin, Poland. maciej.banach@kul.pl.ORCID http://orcid.org/0000-0001-6690-6874

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this meta-analysis was to compare the efficacy of PCSK9 and ANGPTL3 inhibitors in patients with homozygous familial hypercholesterolemia (HoFH).

methodsWe systematically searched selected electronic databases until 30 November 2024. Main end point was the effect of lipid lowering therapy on lipid profile: total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and lipoproteins levels. The secondary end point was adverse clinical effects.

resultsA total of 12 trials involving 392 patients with HoFH, were finally included in the meta-analysis. At a median follow-up of 12 months, ANGPTL3 inhibitors achieved greater reductions in TC (- 49.9% versus - 21.2%; p

conclusionsPCSK9 inhibitors have lower efficacy in reducing lipid levels in HoFH compared with ANGPTL3 inhibitors, with the greatest difference seen in patients with the negative LDLR genotype. Further studies are needed to clarify efficacy across LDLR functional variants.

Indexed as

Angiopoietin-Like Protein 3Angiopoietin-like ProteinsAnticholesteremic AgentsHyperlipoproteinemia Type IIPCSK9 InhibitorsCholesterol, HDLCholesterol, LDLHomozygoteHumansProprotein Convertase 9Randomized Controlled Trials as TopicTriglyceridesAngiopoietin-Like Protein 3Angiopoietin-like ProteinsANGPTL3 protein, humanAnticholesteremic AgentsCholesterol, HDLCholesterol, LDLPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Triglycerides

Identifiers

PMID41501311

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.